RE: For comparisonBased on info re. RIM it would be interesting to know RIM annual EBITA and the multpile the market gives RIM based on EBITA. And then compare potential to MBX, however it is probally better to take a existing biotech with revenue to do a potential comparison, maybe one of the mid size Canadian biotech companies with reasonable revenues and EBITA?